Natalizumab
Links shared publicly online about this topic
Information on Natalizumab (marketed as Tysabri)
fda.gov — “Information on Natalizumab (marketed as Tysabri)” View full resource at fda.gov
Most Recently Shared on September 16, 2009 at 7:36 pm By:
Gannett Healthcare Health News
FDA receives reports of PML in patients receiving Tysabri: http://bit.ly/SD3Nr
Natalizumab and PML in MS - Introduction
medmerits.com — “Natalizumab and PML in MS - Introduction” View full resource at medmerits.com
Most Recently Shared on October 22, 2011 at 8:36 pm By:
@jcberrypdx Detailed scientific article re: Tysabri and PML in MS http://t.co/Vr0NywbT Stats included are from 2009 but good otherwise.
FDA Alert: Natalizumab (marketed as Tysabri)
drugs.com — “FDA Alert: Natalizumab (marketed as Tysabri)” View full resource at drugs.com
Most Recently Shared on September 18, 2009 at 2:16 am By:
FDA Alert - FDA Reports PML Cases in Tysabri (natalizumab) Patients - http://bit.ly/tvthZ
Tysabri (Natalizumab): Update of Healthcare Professional Information
fda.gov — “Risk of developing progressive multifocal leukoencephalopathy (PML) increases with increasing duration of exposure to Tysabri.” View full resource at fda.gov
Most Recently Shared on February 5, 2010 at 4:43 pm By:
eyeonfda Health Lawyer and Pharma
FDA MedWatch updates on Tysabri - http://ow.ly/14hlb - PML Risk increases with number of infusions.
ingentaconnect Natalizumab: Malignant melanoma: case report
ingentaconnect.com — “ingentaconnect Natalizumab: Malignant melanoma: case report” View full resource at ingentaconnect.com
Most Recently Shared on March 7, 2011 at 10:50 am By:
Natalizumab: Malignant melanoma: case report: (Source: Reactions) http://bit.ly/hJgkSt
Tysabri (natalizumab), PML (progressive multifocal leukoencephalopathy), and Ongoing Research - Multiple Sclerosis
healthcentral.com — “Of the available disease-modifying treatments for multiple sclerosis, Tysabri (natalizumab) has arguably been the most controversial to date. The reason f...” View full resource at healthcentral.com
Most Recently Shared on December 17, 2010 at 2:27 am By:
Tysabri (natalizumab), PML (progressive multifocal leukoencephalopathy), and Ongoing Research http://ow.ly/1ausyL
FDA Alert: Tysabri (Natalizumab): Update of Healthcare Professional Information
drugs.com — “FDA Alert: Tysabri (Natalizumab): Update of Healthcare Professional Information” View full resource at drugs.com
Most Recently Shared on February 7, 2010 at 10:06 pm By:
FDA Alert - Revisions to Prescribing Information for Tysabri (natalizumab) - http://bit.ly/b2C46Z
FDA Alert: Tysabri (natalizumab): Update of Healthcare Professional Information
drugs.com — “FDA Alert: Tysabri (natalizumab): Update of Healthcare Professional Information” View full resource at drugs.com
Most Recently Shared on April 23, 2011 at 11:06 pm By:
FDA Alert - Update of Healthcare Professional Information: Tysabri (natalizumab) - http://bit.ly/dV3ExV
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
neurology.org — “Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis” View full resource at neurology.org
Most Recently Shared on May 31, 2011 at 1:50 pm By:
Neurology Journal Medical Journal and Neurology
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis http://bit.ly/lr1HsA #neurology
Multiple Sclerosis Research: Natalizumab PML Update - Aug 2011
multiple-sclerosis-research.blogspot.com — “Multiple Sclerosis Research: Natalizumab PML Update - Aug 2011” View full resource at multiple-sclerosis-research.blogspot.com
Most Recently Shared on October 22, 2011 at 8:28 pm By:
@jcberrypdx Nice graphs re: PML risk and JCV status as of Aug update with 159 Tysabri-PML cases http://t.co/erz6XWCj
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
neurology.org — “Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy” View full resource at neurology.org
Most Recently Shared on May 19, 2011 at 12:05 pm By:
Neurology Journal Medical Journal and Neurology
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy http://bit.ly/iWCksZ #neurology
Medical News: AAN: Another Polyomavirus Appears Reactivated with Natalizumab - in Meeting Coverage, AAN from MedPage Today
medpagetoday.com — “SEATTLE -- The JC polyomavirus responsible for progressive multifocal leukoencephalopathy (PML) may not be the only such virus reactivated by natalizumab (Tysabri).” View full resource at medpagetoday.com
Most Recently Shared on April 28, 2009 at 11:34 pm By:
AAN: Another Polyomavirus Appears Reactivated with Natalizumab http://medpagetoday.com/13950
Medical News: AAN: Studies Nix Natalizumab Holidays - in Meeting Coverage, AAN from MedPage Today
medpagetoday.com — “HONOLULU -- Relapses and/or disease progression are common among multiple sclerosis patients taking natalizumab (Tysabri) who stop the drug, casting doubt on drug holidays as a strategy for minimizi” View full resource at medpagetoday.com
Most Recently Shared on April 12, 2011 at 11:20 pm By:
AAN: Studies Nix Natalizumab Holidays (CME/CE) http://bit.ly/eBRhwp
Medical News: FDA Updates PML Risk Info for Natalizumab - in Neurology, Multiple Sclerosis from MedPage Today
medpagetoday.com — “As expected, the FDA has approved new label language for the multiple sclerosis drug natalizumab (Tysabri) with additional detail on the risks of progressive multifocal leukoencephalopathy (PML).” View full resource at medpagetoday.com
Most Recently Shared on April 22, 2011 at 8:31 pm By:
Thomas Loarie, Jr Health Advocate
@medpagetoday FDA Updates PML Risk Info for Natalizumab http://bit.ly/i6ZA0J #medical #Health
Medical News: JC Virus Activation Called Common with Natalizumab - in Neurology, Multiple Sclerosis from MedPage Today
medpagetoday.com — “The virus responsible for progressive multifocal leukoencephalopathy (PML) showed up in blood and urine in a majority of a small series of multiple sclerosis patients taking natalizumab (Tysabri) for” View full resource at medpagetoday.com
Most Recently Shared on September 10, 2009 at 12:36 am By:
JC Virus Activation Called Common with Natalizumab (CME/CE) http://ow.ly/15OptQ
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Gannett Healthcare
Nursing Spectrum, NurseWeek and www.Nurse.com
-
Lisa Emrich
Patient Advocate and Blogger, Living with Multiple Sclerosis and Rheumatoid Arthritis, Musician, Educator, and writer for HealthCentral.com
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
Advertisement
